Lantheus Tau PET Tracer Meets Phase 3 Targets

Florquinitau F 18 showed high sensitivity and specificity in two pivotal studies, adding a second tau imaging option alongside flortaucipir.

Updated on Nov. 17, 2026 in Alzheimer’s

Vector-style editorial illustration of a white PET scanner gantry beside a grey lead shielding cylinder in an empty clinical imaging room, conveying diagnostic brain imaging equipment.
Lantheus Holdings said two pivotal phase 3 studies of its tau PET imaging agent florquinitau F 18 met all prespecified reader-agreement targets, adding a second option to flortaucipir. AI Illustration. Upload story photo >

Lantheus Holdings announced results from two pivotal phase 3 studies of florquinitau F 18 injection, a tau PET imaging agent, with all five independent readers meeting the prespecified coprimary end points of sensitivity and specificity. The data were presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 meeting in Boston, Massachusetts, and support the Tauklarify FDA-approved use.

Why it matters

Tau PET imaging helps clinicians identify tau pathology in people with cognitive impairment, and florquinitau F 18 would join flortaucipir F 18 as an available option. Consistent reader agreement across the studies is a key factor in whether the tracer can be used reliably in routine clinical assessment.

Pivotal reader-performance data from 617 combined PET scans show majority-read sensitivity of 87.8% and 78.8% and specificity of 98.6% and 99.4% across the two studies, measured against a prospectively defined clinical and radiographic reference standard. Whether these figures hold across broader, non-trial patient populations has not been addressed in the reported results.

The players

Lantheus Holdings

Lantheus Holdings is a radiopharmaceutical company that develops and commercializes diagnostic imaging agents, including PET tracers used in neurology.

The details

Florquinitau F 18 is a fluorine 18-labeled radiotracer that binds aggregated tau, and the two studies drew scans from three established prospective Alzheimer disease studies. Safety was assessed in a pooled analysis of 1734 participants from the US POINTER and AIBL studies, with the most common treatment-emergent adverse events being headache (0.7%), nausea (0.2%), dizziness (0.1%), injection site reactions (0.1%), and abdominal discomfort (0.1%).

Timeline

  1. November 16, 2026: Lantheus issued its news release on the phase 3 results.

  2. 2020: The FDA approved flortaucipir F 18 (Tauvid), the existing tau PET option.

  3. CTAD 2026 meeting: Phase 3 data were presented in Boston, Massachusetts.

Roadmap

Florquinitau F 18 follows the path Tauvid opened in 2020, when the FDA approved flortaucipir F 18 as the first tau PET imaging agent. Adding a second tracer with pivotal data of this kind gives clinicians more than one tau imaging option as tau pathology assessment becomes more central to Alzheimer's evaluation.

For people being evaluated for cognitive impairment, a second FDA-reviewed tau PET tracer could expand the imaging options their clinicians can choose from. The data reported so far do not change what a patient will experience during a scan, and availability will depend on regulatory action and clinical adoption.

The takeaway

Consistent reader agreement across two independent pivotal studies is the core result to watch, since that consistency is what determines whether a PET tracer can be read reliably outside a research setting. Clinicians evaluating cognitive impairment should track regulatory decisions on florquinitau F 18 before assuming it is available.

Further reading

For more on how tau imaging fits into diagnosis, see the Alzheimer’s section.